Rangeley Capital LLC Acquires New Holdings in Liquidia Co. (NASDAQ:LQDA)

Rangeley Capital LLC purchased a new position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 191,000 shares of the company's stock, valued at approximately $2,246,000. Liquidia accounts for approximately 2.0% of Rangeley Capital LLC's holdings, making the stock its 15th largest holding. Rangeley Capital LLC owned 0.23% of Liquidia as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC acquired a new position in shares of Liquidia during the fourth quarter worth about $59,000. Walleye Trading LLC boosted its stake in shares of Liquidia by 54.7% during the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company's stock worth $132,000 after acquiring an additional 4,670 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Liquidia during the 4th quarter worth $154,000. KLP Kapitalforvaltning AS acquired a new position in Liquidia during the fourth quarter worth about $169,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Liquidia by 43.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company's stock valued at $187,000 after buying an additional 5,669 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Analysts Set New Price Targets

LQDA has been the topic of a number of recent research reports. Wells Fargo & Company started coverage on shares of Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 target price on the stock. Scotiabank reiterated an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. Finally, Needham & Company LLC upped their target price on Liquidia from $19.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $26.63.

Remove Ads

Insider Activity at Liquidia

In other news, insider Rajeev Saggar sold 2,445 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the transaction, the insider now directly owns 267,943 shares in the company, valued at approximately $3,483,259. This trade represents a 0.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the sale, the chief executive officer now owns 1,019,177 shares in the company, valued at approximately $12,005,905.06. This trade represents a 2.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock valued at $843,326 over the last three months. 30.10% of the stock is owned by insiders.

Liquidia Price Performance

NASDAQ LQDA traded up $0.01 on Tuesday, reaching $12.44. The company had a trading volume of 359,376 shares, compared to its average volume of 947,440. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.81. The firm has a 50-day moving average of $15.10 and a 200-day moving average of $12.61. The firm has a market capitalization of $1.06 billion, a PE ratio of -7.65 and a beta of 0.23.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million for the quarter, compared to analysts' expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, sell-side analysts expect that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).